L
Lukas Smolej
Researcher at Charles University in Prague
Publications - 110
Citations - 1466
Lukas Smolej is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Chronic lymphocytic leukemia & Rituximab. The author has an hindex of 18, co-authored 102 publications receiving 1268 citations. Previous affiliations of Lukas Smolej include University of Florida.
Papers
More filters
Journal ArticleDOI
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz,Jacqueline C. Barrientos,Jennifer R. Brown,Bertrand Coiffier,Julio Delgado,Miklos Egyed,Paolo Ghia,Árpád Illés,Wojciech Jurczak,Paula Marlton,Marco Montillo,Franck Morschhauser,Alexander S. Pristupa,Tadeusz Robak,Jeff P. Sharman,David Simpson,Lukas Smolej,Eugen Tausch,Adeboye H. Adewoye,Lyndah Dreiling,Yeonhee Kim,Stephan Stilgenbauer,Peter Hillmen +22 more
TL;DR: Ielalisib plus BR is superior to BR alone, improving PFS and OS, and represents an important new treatment option for patients with R/R CLL.
Journal ArticleDOI
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
William G. Wierda,Thomas J. Kipps,Jan Dürig,Laimonas Griskevicius,Stephan Stilgenbauer,Jiří Mayer,Lukas Smolej,Georg Hess,Rasa Griniute,Francisco J. Hernandez-Ilizaliturri,Swaminathan Padmanabhan,Michele Gorczyca,Chai Ni Chang,Geoffrey W. Chan,Ira Gupta,Tina Nielsen,Charlotte A. Russell +16 more
TL;DR: O-FC is active and safe in treatment-naive patients with CLL, including high-risk patients, and β2-microglobulin and the number of O-FC courses were significantly correlated with CR and OR rates and progression-free survival (PFS).
Journal ArticleDOI
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
Marinus H. J. van Oers,Kazimierz Kuliczkowski,Lukas Smolej,Mario Petrini,Fritz Offner,Sebastian Grosicki,Mark-David Levin,Ira Gupta,Jennifer Phillips,Vanessa C. Williams,Stephanie Manson,Steen Lisby,Christian H. Geisler +12 more
TL;DR: The efficacy and safety of ofatumumab maintenance treatment versus observation for patients in remission after re-induction treatment for relapsed chronic lymphocytic leukaemia and the results of a prespecified interim analysis are reported.
Journal ArticleDOI
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
Chan Yoon Cheah,Chan Yoon Cheah,Anupkumar George,Eva Giné,Annalisa Chiappella,Hanneke C. Kluin-Nelemans,Wojciech Jurczak,Katarzyna Krawczyk,Heidi Mocikova,Pavel Klener,David Šálek,Jan Walewski,Michal Szymczyk,Lukas Smolej,Rebecca Auer,David Ritchie,David Ritchie,Luca Arcaini,Michael E. Williams,Martin Dreyling,John F. Seymour,John F. Seymour +21 more
TL;DR: In MCL, central nervous system involvement is uncommon, although some features may predict risk, and once manifest outlook is poor, some patients who receive intensive therapy survive longer than 12 months.
Journal ArticleDOI
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
Reinhard Stauder,Barbara Eichhorst,Marije E. Hamaker,K. Kaplanov,Vicki A. Morrison,Anders Österborg,I. Poddubnaya,Jennifer A. Woyach,Tait D. Shanafelt,Lukas Smolej,L. Ysebaert,Valentin Goede +11 more
TL;DR: Current available evidence relevant to elderly patients with CLL is reviewed, including the relationship between chronological age, prognosis and survival, assessment of biological aging, and biological age as a determinant of treatment feasibility and tolerance.